Anthony E. Boitano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anthony E. Boitano has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer L. Snead
Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA.
1 shared publication Lorenzo de Lichtervelde
Department of Chemistry, The Scripps Research Institute, La Jolla, Ca 92037; and
1 shared publicationMichael P. Cooke
Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121
1 shared publication- Peter G. Schultz
Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
1 shared publication
Latest Publications
- 13 August 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (35) , 14019-14023
An image-based screen identifies a small molecule regulator of megakaryopoiesis
Molecules that control the lineage commitment of hematopoietic stem cells (HSCs) may allow the expansion of enriched progenitor populations for both research and therapeutic uses. In an effort to better understand and control the differentiation of HSCs to megakaryocytes, we carried out an image-based screen of a library of 50,000 heterocycles using primary human CD34 + cells. A class of naphthyridinone derivatives was identified that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes. Kinase profiling and subsequent functional assays revealed that these compounds act through inhibition of platelet-derived growth factor receptor (PDGFR) signaling in CMPs. Such molecules may ultimately have clinical utility in the treatment of thrombocytopenia.
- 13 August 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (35) , 14019-14023
An image-based screen identifies a small molecule regulator of megakaryopoiesis
Molecules that control the lineage commitment of hematopoietic stem cells (HSCs) may allow the expansion of enriched progenitor populations for both research and therapeutic uses. In an effort to better understand and control the differentiation of HSCs to megakaryocytes, we carried out an image-based screen of a library of 50,000 heterocycles using primary human CD34 + cells. A class of naphthyridinone derivatives was identified that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes. Kinase profiling and subsequent functional assays revealed that these compounds act through inhibition of platelet-derived growth factor receptor (PDGFR) signaling in CMPs. Such molecules may ultimately have clinical utility in the treatment of thrombocytopenia.